Morgan Stanley Initiates Coverage on Omada Health (NASDAQ:OMDA)

Equities research analysts at Morgan Stanley began coverage on shares of Omada Health (NASDAQ:OMDA - Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set an "overweight" rating and a $25.00 price target on the stock. Morgan Stanley's price target indicates a potential upside of 36.61% from the stock's current price.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group began coverage on shares of Omada Health in a report on Tuesday. They issued a "buy" rating and a $27.00 target price for the company. Wall Street Zen upgraded shares of Omada Health to a "hold" rating in a research note on Monday, June 16th. The Goldman Sachs Group assumed coverage on Omada Health in a report on Tuesday. They issued a "buy" rating and a $29.00 target price for the company. Needham & Company LLC assumed coverage on Omada Health in a research note on Tuesday. They set a "buy" rating and a $23.00 price target on the stock. Finally, Barclays initiated coverage on Omada Health in a research note on Tuesday. They issued an "overweight" rating and a $21.00 price objective for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $24.00.

Omada Health Stock Performance

Shares of NASDAQ OMDA opened at $18.30 on Tuesday. Omada Health has a fifty-two week low of $14.14 and a fifty-two week high of $28.40.

About Omada Health

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.